Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 7, 2016, Pages 1300-1306

  Chan, Anthony W H ^a   Kumada, Takshi ^b   Toyoda, Hidenori ^b   Tada, Toshifumi ^b   Chong, Charing C N ^c   Mo, Frankie K F ^a   Yeo, Winnie ^a   Johnson, Philip J ^d   Lai, Paul B S ^b,d   Chan, Anthony T C ^a   To, Ka Fai ^a,c   Chan, Stephen L ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

albumin; Barcelona Clinic Liver Cancer (BCLC); bilirubin; Child Pugh score; liver function; prognosis; survival; tumor staging

Indexed keywords

ALBUMIN; BILIRUBIN; SERUM ALBUMIN; TUMOR MARKER;

ADULT; AGED; ALBUMIN BILIRUBIN SCORE; ALBUMIN BLOOD LEVEL; ARTICLE; BARCELONA CLINIC LIVER CANCER SYSTEM; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FEMALE; HONG KONG; HUMAN; JAPAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; UNITED KINGDOM; BLOOD; LIVER TUMOR; MULTICENTER STUDY (TOPIC); PATHOLOGY; PATIENT SELECTION; PROCEDURES; PROGNOSIS;

AGED; BILIRUBIN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; SERUM ALBUMIN;

EID: 84979498142     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13291     Document Type: Article

References (24)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN. In: v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11Internet. Lyon, France: International Agency for Research on Cancer, 2012.
2. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751–5.
3. Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396–405.
4. European Association for the Study of the Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908–43.
5. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2.
6. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J. Hepatol. 2005; 42: S100–7.
7. Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 2015; 33: 550–8.
8. Knox JJ. Addressing the interplay of liver disease and hepatocellular carcinoma on patient survival: the ALBI scoring model. J. Clin. Oncol. 2015; 33: 529–31.
9. Chan SL, Mo FK, Johnson PJ et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J. Gastroenterol. Hepatol. 2011; 26: 340–7.
10. Chan AW, Chan SL, Mo FK et al. Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Dis. Markers 2015; 2015: 10.
11. Ueno S, Tanabe G, Sako K et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001; 34: 529–34.
12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646–9.
13. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7: 660–4.
14. Fujii M, Yasunaga K, Uchino H. Correlation analysis of relationships between vitamin-K-dependent clotting factors and effective hepatic blood flow, albumin and other liver function tests. Haemostasis 1980; 9: 9–14.
15. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann. Hepatol. 2002; 1: 72–9.
16. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig. Liver Dis. 2010; 42: 341–7.
17. Chan AW, Chan RC, Wong GL et al. Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. Histopathology 2014; 65: 174–86.
18. Chan AW, Chan RC, Wong GL et al. New simple prognostic score for primary biliary cirrhosis: albumin–bilirubin score. J. Gastroenterol. Hepatol. 2015; 30: 1391–6.
19. Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac. J. Clin. Oncol. 2013; 9: 2–5.
20. Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707–16.
21. Chan SL, Johnson PJ, Mo F et al. International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin. J. Cancer 2014; 33: 481–91.
22. Roayaie S, Jibara G, Tabrizian P et al. Hepatology: The role of hepatic resection in the treatment of hepatocellular cancer, 2015.
23. D'Avola D, Inarrairaegui M, Pardo F et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann. Surg. Oncol. 2011; 18: 1964–71.
24. Vitale A, Morales RR, Zanus G et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol. 2011; 12: 654–62.